Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
5 minute read

Psyched: Australia Legalizes Psychedelics Therapy, BC’s Decrim, State Bills, Millions For Trials & Clinics

By Lara Goldstein
Today, 6:01 AM
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.

CSE:ORIG

Read More
2 minute read

Psychedelics Investor Acquires Firm With First-Mover Advantage In Safe Supply Narcotics Sector

By Joana Scopel
Today, 6:01 AM
Late Tuesday, Origin Therapeutics Holdings Inc. (CSE: ORIG), an investment issuer that has historically focused on psychedelics-industry-related companies announced it had signed a binding Letter of Intent (LOI) to acquire all of the issued and outstanding securities of Safe Supply Streaming Co., a pharmaceutical streaming and investment company in the safe supply eco

CSE:ORIG

Read More
1 minute read

Magic Mushrooms For Anorexia? Clinical Study Receives FDA Approval For Phase 2 Trial

By Lara Goldstein
Today, 6:01 AM
Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a Phase 2a psilocybin therapy clinical study for anorexia nervosa.

CSE:ORIG